Vemlidy Approval History
- FDA approved: Yes (First approved November 10th, 2016)
- Brand name: Vemlidy
- Generic name: tenofovir alafenamide
- Dosage form: Tablets
- Company: Gilead Sciences, Inc.
- Treatment for: Hepatitis B
Vemlidy (tenofovir alafenamide) is a hepatitis B virus (HBV) nucleoside analog reverse transcriptase inhibitor indicated for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease.
FDA approval of Vemlidy was supported by data from two Phase 3 studies among 1,298 treatment-naïve and treatment-experienced adult patients with chronic HBV infection who were randomly assigned and treated with either Vemlidy or Viread (tenofovir disoproxil fumarate). In both studies, Vemlidy proved to have efficacy similar to Viread, but with improved renal and bone laboratory safety parameters.
Vemlidy is an oral tablet taken once daily with food. Vemlidy carries a boxed warning advising risks for lactic acidosis/severe hepatomegaly with steatosis and post-treatment severe acute exacerbation of hepatitis B. Common side effects include headache, abdominal pain, fatigue, cough, nausea, and back pain.
Development History and FDA Approval Process for Vemlidy
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.